Medicare Part B premiums are going up by 9.7% in 2026. - Getty Images Blame medical inflation and more people in need of costly care for the 9.7% jump in Medicare Part B premiums next year. Starting in January, people on Medicare will pay $202.90 in 2026 for their monthly Part B premiums, which provide coverage for services like doctor’s visits, outpatient procedures and medications administered by a healthcare professional. That’s up from $185.00 in 2025. Most Read from MarketWatch The government has ...

Core Insights - Eli Lilly has achieved a historic milestone by surpassing a market capitalization of $1 trillion, becoming the first pharmaceutical company to join the "trillion-dollar club," breaking the long-standing dominance of tech giants [1] - The surge in Eli Lilly's stock price, which has increased over 35% this year, is primarily driven by the explosive growth in the obesity drug market, positioning the company as a leader in the metabolic health sector [1][2] Financial Performance - Eli Lilly's obesity and diabetes product line generated $10.09 billion in revenue, accounting for over half of the company's total revenue of $17.6 billion, making it the core driver of performance growth [3] - The company has raised its full-year revenue forecast by over $2 billion due to the increasing global demand for obesity and diabetes medications [3] Market Outlook - Analysts predict that the global obesity drug market will reach $150 billion by 2030, with Eli Lilly and Novo Nordisk expected to dominate this market [3] - The upcoming approval of Eli Lilly's oral obesity treatment, orforglipron, is anticipated to be a significant growth driver, benefiting from the established market presence of its injectable counterparts [3] Strategic Developments - A collaboration agreement with the Trump administration aims to invest billions to enhance domestic production capacity, potentially increasing the number of patients eligible for obesity treatment by 40 million in the U.S. [4] - Eli Lilly is being viewed as a new investment choice among major players, akin to tech giants, due to its strong performance and growth potential [5] Challenges and Considerations - The market is closely monitoring whether Eli Lilly can maintain its growth momentum amid pricing pressures on Mounjaro and Zepbound, as well as the effectiveness of its expansion plans and diversification strategies [6]

By Mrinalika Roy (Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse. A more than 35% rally in the company's ​stock this year has largely been driven by the explosive growth of the weight-loss drug market. In the last two years as new, highly effective ‌obesity treatments hit the market, the category has emerged as one of the most lucrative segments in heal ...

With the end of the pandemic, sales of Pfizer’s (PFE) COVID products, Comirnaty and Paxlovid, declined from their peak. However, Pfizer’s non-COVID operational revenues are improving, driven by its key in-line products like Vyndaqel, Padcev and Eliquis, recent launches and newly acquired products like Nurtec and those from Seagen (December 2023).The year 2023 was a record year for Pfizer in terms of new drug approvals. It received nine new medicine/vaccine approvals in 2023 that have begun to contribute to ...

Core Viewpoint - Goldman Sachs predicts that the S&P 500 will achieve an average annual gain of only 6.5% over the next decade, a significant decrease from the historical average of around 10% [2] Valuation Concerns - U.S. stocks are currently considered expensive, with the S&P 500's trailing price-to-earnings ratio near a multiyear high of 23 [4] - The valuation issue is exacerbated by a few large companies in the AI sector, which may lead to a broader market correction, potentially reducing market progress by about 1% per year through 2035 [5] Interest Rates Impact - The widening of the S&P 500's profit margins since 1990 has been largely due to falling interest rates and corporate tax rates, neither of which are expected to decline significantly in the next decade [6] Strategic Adjustments - Investors are encouraged to diversify their portfolios by considering stocks outside the current market favorites [7] - International markets, particularly in Japan and Asia, are projected to perform better, with average market growth outlooks of 8.2% and 10.3% respectively, and emerging markets expected to yield 10.9% annualized returns through 2035 [8] Spotlight on Foreign Stocks - Companies like Alibaba and MercadoLibre are highlighted as potential investment opportunities, with Alibaba focusing on AI for growth and MercadoLibre benefiting from the rise of web-connected smartphones in South America [9] Currency Dynamics - Both Alibaba and MercadoLibre's American depositary receipts are denominated in U.S. dollars, which may provide an additional 2 percentage points of net growth annually as the dollar is considered overvalued [11] Importance of Dividends - Dividends are expected to play a crucial role in total returns across all regions, benefiting dividend-focused companies like Coca-Cola and pharmaceutical firms such as Pfizer and Merck [12][13] Market Adaptation - Investors are advised to adapt their strategies in response to changing market conditions, including interest rates, government debt, and competitive dynamics introduced by AI [15]

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Anaptysbio and its partner GSK are suing each other, claiming breach of contract over the big drugmaker’s license to market the likely blockbuster cancer immunotherapy Jemperli. A California-based developer of immune-modulating antibody drugs, Anaptysbio claimed in a Delaware court that GSK violated the terms of its decade-old deal by testing some of its experi ...

Core Viewpoint - AnaptysBio has filed a Verified Complaint against Tesaro and GSK, alleging material breaches of their Collaboration Agreement and seeking legal remedies [1][2]. Group 1: Legal Dispute - The Complaint asserts that Tesaro breached the Collaboration Agreement by engaging in clinical trials with competing PD-1 antagonists, including Keytruda, and failed to use reasonable efforts to maximize commercial returns for Jemperli [2]. - Anaptys previously filed a complaint against GSK in 2020 for similar breaches related to GSK's clinical trial of Zejula in combination with Keytruda, which resulted in a settlement that included cash payments and increased royalties on Jemperli [3]. - Tesaro has initiated its own lawsuit against Anaptys, claiming that Anaptys has breached the Collaboration Agreement, which Anaptys contends is without merit [4]. Group 2: Collaboration Agreement Details - The Collaboration Agreement, established in March 2014, involves Tesaro developing Jemperli for various solid tumor indications [6]. - Anaptys is entitled to royalties from Jemperli sales, structured as 8% for net sales below $1 billion, 12% for sales between $1 billion and $1.5 billion, 20% for sales between $1.5 billion and $2.5 billion, and 25% for sales above $2.5 billion [7]. - A one-time $75 million commercial sales milestone is anticipated once Jemperli achieves $1 billion in worldwide net sales [7]. Group 3: Financial Implications - The royalty term under the Collaboration Agreement extends until the expiration of composition of matter coverage, which is set to expire in 2035 in the U.S. and 2036 in the EU [8]. - Anaptys estimates that Sagard will have accrued $250 million in royalties and sales milestones through the end of 2025, with full paydown of $600 million expected between Q2 2027 and Q2 2028 [9]. Group 4: Future Developments - The parties have agreed to an expedited schedule with the Delaware Chancery Court, with a trial anticipated in July 2026 [5]. - Milestone and royalty payment obligations to Anaptys will continue during the legal proceedings [5].

Core Insights - Merck announced positive top-line results from a pivotal late-stage study for its investigational HIV treatment DOR/ISL, demonstrating non-inferiority to Gilead's Biktarvy [1][4][6] Group 1: Study Results - The phase III MK-8591A-053 study evaluated DOR/ISL in treatment-naïve adults with HIV-1, showing comparable efficacy and safety to Gilead's Biktarvy [3][4] - The study met its primary endpoint, with a significant percentage of patients achieving HIV-1 RNA levels below 50 copies/mL at week 48 [4][8] - DOR/ISL's safety profile was found to be similar to that of Biktarvy, supporting its potential as a treatment option [4][8] Group 2: Regulatory and Market Implications - A regulatory filing for DOR/ISL to treat virologically suppressed adults on antiretroviral therapy is under FDA review, with a decision expected on April 28, 2026 [2] - Merck plans to present detailed results from the MK-8591A-053 study at a future medical conference and is preparing applications for approval to treat treatment-naïve HIV patients [5][6] - Year-to-date, Merck's shares have decreased by 4.4%, contrasting with the industry's growth of 14.5% [5] Group 3: Additional Developments - The European Commission approved the subcutaneous formulation of Keytruda, enhancing patient convenience and potentially increasing adoption rates [10][12] - The SC version of Keytruda can be administered in as little as one minute, compared to at least 30 minutes for the IV formulation, easing the burden on healthcare facilities [12][13]

Key Points Merck's newest acquisition grants it access to a highly promising medicine. That could help it overcome the challenges its two biggest franchises are facing. Merck has other things going its way, including a deep pipeline and a strong dividend. 10 stocks we like better than Merck › Over the past two years, Merck (NYSE: MRK) has faced several challenges, resulting in a decline in the company's share price. Even worse, the pharmaceutical giant could face more issues ahead, including the ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [2] Core Insights - Eli Lilly's revenue increased by 52% year-on-year in Q3 2025, driven by GLP-1 drugs, with Tirzepatide's quarterly revenue exceeding $10 billion for the first time, showing a 131% year-on-year growth [4] - Novo Nordisk faced intensified competition in the weight loss drug market, leading to a modest revenue growth of 1% for Ozempic and 6% for Wegovy in Q3 2025, prompting a downward revision of its annual performance guidance [4] - A total of 11 out of 16 companies in the report raised their revenue and/or net profit/EPS forecasts for the year, primarily due to better-than-expected sales of new products [4] Summary by Sections 1. Q3 2025 Performance Review - Eli Lilly's Q3 revenue reached $17.6 billion, with a 62% increase in sales volume, while net prices decreased by 10% [12] - Novo Nordisk's sales revenue for Q3 was 75 billion Danish Kroner, with a net profit decline of 27% [13] - JNJ's pharmaceutical segment achieved revenue of $15.6 billion, with significant contributions from oncology and neurology products [14] - AbbVie reported global sales of $15.8 billion, with notable growth in immunology and neurology sectors [15] - Gilead's revenue for Q3 was $7.3 billion, with a 4% increase in HIV product sales [16] 2. MNC Product Performance in the U.S. Market - The median time for MNC products to reach peak sales in the U.S. market is approximately 8 years, with first-in-class (FIC) products achieving this in about 7 years [4] 3. Revenue and Guidance Adjustments - Eli Lilly raised its full-year revenue guidance from $60-62 billion to $63-63.5 billion [12] - Novo Nordisk revised its revenue growth forecast down from 8%-14% to 8%-11% [13] - JNJ increased its full-year revenue guidance from $93.2-93.6 billion to $93.5-93.9 billion [14]